BioCentury
ARTICLE | Clinical News

Cinfa biosimilar shows equivalence to Neulasta

May 18, 2017 12:23 AM UTC

The Cinfa Biotech S.L. subsidiary of Infarco Group (Olloki, Spain) said biosimilar candidate B12019 met the primary and secondary endpoints in a Phase I trial by showing comparability to reference product Neulasta pegfilgrastim from Amgen Inc. (NASDAQ:AMGN). Cinfa is planning to submit the candidate to EU regulators next half...

BCIQ Company Profiles

Infarco Group